Eli Lilly’s lebrikizumab significantly improves atopic dermatitis in Phase III trial
pharmafile | August 16, 2021 | News story | Sales and Marketing |
Eli Lilly’s lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase III trials.
The drug led to significant improvements with at least 75 percent skin clearance in more than half of people with moderate-to-severe atopic dermatitis (AD), as measured by EASI.
Lebrikizumab has been granted fast track designation by the FDA.
Fast Track designation is granted for a medicine that is intended to treat a serious condition and data demonstrate the potential to address an unmet medical need.
Jonathan Silverberg, Associate Professor of Dermatology at George Washington University School of Medicine and Health Sciences in Washington, and a Principal Investigator of the trial, said: “AD is a heterogenous disease with signs and symptoms varying greatly between patients, underscoring the need for additional treatment options with different mechanisms of action.
“Data from the studies showed lebrikizumab’s effect on skin clearance and its potential to address a key driver for this disease as well as provide improvements in itch, sleep disturbance and quality of life.”
Lotus Mallbris, Vice President of Immunology Development at Lilly, said: “We understand the needs of people in the AD community worldwide and are aware that many are still in need of new treatment options despite available medicines.
“Lebrikizumab is a specific inhibitor of IL-13 that offers robust binding affinity and high bioavailability. Today’s results show that the inhibition of IL-13 cytokine plays a main role in AD treatment, as demonstrated by more than half of the patients achieving at least 75% clearance to total clearance on lebrikizumab monotherapy.”
AD, also known as atopic eczema, is a chronic inflammatory skin disorder caused by skin barrier dysfunction and dysregulation of the immune response. People living with AD often report symptoms of intense, persistent itch which can be so uncomfortable that it can affect sleep, daily activities and social relationships.
Lilly Subbotin
